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ABSTRACT
Objective: Carbon nanomaterials (CNMs) such as carbon nanofibres (CNFs), multi-wall carbon nanotubes (MWCNTs), and carbon nanorods (CNRs) 
were found various industrial and commercial applications. The occupational exposure for these CNMs was also increased enormously. This study 
evaluated the extrapulmonary toxicity induced by these CNMs.
Methods: The extrapulmonary toxicity was assessed following intratracheal instillation of test CNMs in rats after 1 day, 1 week, 1 month, and 3 months 
postexposure periods using serum biochemical parameters such as alanine transaminase (ALT) and creatinine using diagnostic assay kits. Further, the 
histopathological analysis was performed for liver and kidneys of particle exposed rats.
Results: The results have displayed that increased levels of serum ALT and creatinine were found after 1 day, 1 week, and 1 month postexposure 
periods indicating liver and kidney toxicity, respectively. This toxicity was further confirmed by the changes observed in the histopathological analysis 
of rat liver and kidneys.
Conclusion: The CNFs, MWCNTs, and CNRs able to translocate from the lungs into other extrapulmonary organs such as liver and kidney, and also 
cause dose-dependent toxicity to them.
Keywords: Alanine transaminase, Carbon nanomaterials, Creatinine, Toxicity.
INTRODUCTION
Carbon nanomaterials (CNMs) are a new form of crystalline carbon 
currently attracting intense research efforts because of their unique 
properties that make them suitable, as such or after modification, 
for many industrial developments such as in high strength materials, 
electronics or biomedical applications [1]. With the widespread 
development of commercial CNMs manufacturing and commercial 
application, CNMs such as multi-wall carbon nanotubes (MWCNTs), 
carbon nanofibers (CNF), and carbon nanorods (CNRs) are an important 
category of nanoparticle for health risk assessment. There is a need 
to address the associated bioactivity of these newly manufactured 
nanomaterials [2,3].
Pulmonary retention and extrapulmonary redistribution of inhaled 
nanoparticles have been considered to be important contributing 
factors of cardiorespiratory diseases. Varying the characteristics of 
carbon nanoparticles, such as size, surface charge, attachment of ligands, 
or surfactant coatings, offers the possibility for site-specific targeting 
of different regions of the gastro-intestinal tract. The fast transit of 
material through the intestinal tract (on the order of hours), together 
with the continuous renewal of epithelium, led to the hypothesis that 
nanomaterials will not remain there for indefinite periods [4].
The ingested nanoparticles have eliminated rapidly: 98% in the feces 
within 48 hours and most of the remainder via urine [3]. However, 
other studies indicate that certain nanoparticles can translocate to 
blood, spleen, liver, bone marrow, lymph nodes, kidneys, lungs, brain 
and can also be found in the stomach and small intestine. Oral uptake 
of polystyrene spheres of various sizes (50 nm-3 μm) by rats resulted 
in a systemic distribution to liver, spleen, blood, and bone marrow [5].
Recently, some investigations were evaluated the in vitro toxicity of 
different nanoparticles in human cell lines through various biomarkers 
and reported the cytotoxicity and oxidative stress induction [6-8]. 
Initial studies focused on the respiratory effects of pulmonary exposure 
of various nanoparticles but were limited by the lack of knowledge 
concerning the extra-pulmonary toxicity [9-11]. Some nanoparticles 
characterized by their ability to translocate, from their site of deposition 
in the lungs to the blood and the brain [12,13]. In this study, we have 
evaluated the ability of the MWCNTs, CNFs, and CNRs to translocate into 
extra-pulmonary organs like liver and kidney, and also evaluated the 
extrapulmonary toxicity of these CNMs in rats following intratracheal 
instillation.
METHODS
The MWCNTs, CNFs, and CNRs were purchased from Sigma-Aldrich, 
USA. Quartz powder (QZ) and carbonyl iron (CI) were obtained from 
S.D. Fine chemicals, India. Phosphate buffer saline (PBS) and Tween 80 
were procured from HiMedia Laboratories Ltd., Mumbai. Serum alanine 
transaminase (ALT) and serum creatinine assay kits were purchased 
from Span diagnostics, India.
Experimental animals
Groups of male wistar albino rats (Hyderabad, India) of 6-9 weeks 
old at study start (mean weights in the range of 220-275 g) were 
selected and housed in polypropylene cages in a room where the 
congenial temperature was 26±2°C and 12 hrs light and dark cycles 
were maintained. The animals were allowed to acclimatize to the 
environment for 7 days and supplied with a standard pellet diet and 
water ad libitum. All procedures using animals were reviewed and 
approved by the Institutional Animal Care and Use Committee of 
Kakatiya University.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Preparation of fine-dust suspensions
Fine particle suspensions of CNMs were prepared with a nontoxic 
dispersion vehicle for instillation into rat lungs [14,15]. The 
products are extremely difficult to disperse even in the presence of 
a dispersing agent. All the CNMs suspensions were prepared in PBS 
+ 1% Tween 80 at a concentration of 10 mg/mL by briefly shearing 
(2 minutes in a small glass homogenizing tube) and subsequently 
sonicating (1-2 minutes) the samples. All the samples with different 
concentrations were re-sonicated on the day of dosing before the 
instillation.
Intratracheal instillation
The rats were anesthetized with 3-5% isoflurane in a small 
chamber and individual rats were secured on an inclined plastic 
platform and anesthetization continued via a small nose cone. The 
trachea was exposed by a 1 cm incision on the ventral neck skin 
for instillation of the dust suspension [16]. The intratracheal fast 
instillation/nebulization procedure for rats was modified to ensure 
that instilled material was delivered into the lungs of rats with a 
good distribution [17].
Experimental design
Groups of rats were instilled intratracheally with single dose of 
1 mg/kg or 5 mg/kg of CNF, MWCNT, CNR, CI and quartz-crystalline 
silica particles (QZ). All the particles were prepared in a volume of 
1.0% Tween 80 and phosphate-buffered saline and subjected to 
polytron dispersion [18]. Groups of PBS-Tween, CI, and QZ instilled rats 
were served as solvent control, negative control, and positive control, 
respectively.
Collection of blood samples and biochemical analysis
Blood samples were collected from all the group of rats by retro-
orbital sinus puncture, under mild ether anesthesia and serum 
was obtained by immediate centrifugation of blood samples using 
BIOFUGE cooling centrifuge at 3000 rpm for 10 minutes at room 
temperature. The blood samples were collected from all the group 
of rats at 24 hrs, 1 week, 1 month, and 3 months postinstillation 
intervals and were used to estimate suitable biomarkers (enzyme 
levels) which represent the organ/tissue toxicity. Evaluation of 
ALT levels was specifically used to assess the liver toxicity and 
estimation of serum creatinine levels assesses the renal toxicity. 
The biochemical assays were performed on serum samples for the 
estimation of creatinine and ALT using respective diagnostic kit 
methods.
Histopathological studies of extrapulmonary organs
The extrapulmonary vital organs (liver and kidney) of all the control 
and particles exposed rats were collected at 24 hrs, 1 week, 1 month 
and 3 months postinstillation intervals of CNMs. These tissues were used 
for the histopathological examination to assess the extrapulmonary 
toxicity of CNMs. The isolated tissues were fixed in 10% v/v neutral 
buffered formalin and processed using routine histological techniques. 
The liver and kidney tissues were embedded in paraffin and stained 
using hematoxylin and eosin (H and E) dyes for histopathological 
evaluations.
Statistical analysis
All the experimental values were expressed as mean±standard deviation 
and were compared with control value at each time point. One-way 
analysis of variance and Dunnett test were used to compare means 
Table 1: Serum ALT levels (IU/L) in rats exposed to CNFs, MWCNTs and CNRs
Group Postinstillation period
1 day 1 week 1 month 3 months
PBS+1% Tween 80 29.54±2.12 29.20±0.80 27.60±2.30 26.30±1.23
CI 1 mg/kg 29.92±1.90 30.18±1.23 30.34±3.01 30.09±2.15
CI 5 mg/kg 31.21±2.36 31.84±2.12 31.55±2.18 31.37±3.12
CNFs 1 mg/kg 38.58±4.12* 44.32±4.50** 52.49±4.23*** 46.76±3.56*
CNFs 5 mg/kg 45.15±4.92** 50.54±4.30** 59.97±4.56*** 53.18±4.23**
MWCNTs 1 mg/kg 36.33±3.12* 41.15±3.58** 49.36±3.96** 44.72±2.36*
MWCNTs 5 mg/kg 42.64±4.12* 47.54±3.26** 55.25±4.78*** 51.67±2.47**
CNRs 1 mg/kg 34.13±1.23* 38.28±3.56* 41.47±3.45** 40.61±3.78*
CNRs 5 mg/kg 39.62±2.50* 43.41±3.60** 49.18±3.56** 47.55±3.60**
QZ 1 mg/kg 33.24±3.45* 39.53±3.12* 41.83±3.48** 41.29±2.96*
QZ 5 mg/kg 38.78±4.35* 44.12±1.23** 50.74±3.96** 45.90±2.98*
Data were expressed as mean±SD (n=6), Significance was indicated by *p<0.05, **p<0.01, ***p<0.001 versus control treated rats. ALT: Alanine transaminase, 
BPS: Phosphate buffer saline, CI: Carbonyl iron, CNFs: Carbon nanofibers, MWCNTs: Multi wall carbon nanotubes, CNRs: Carbon nanorods, QZ: Quartz, SD: Standard 
deviation
Table 2: Serum creatinine levels (mg/dL) in rats exposed to CNFs, MWCNTs and CNRs
Group Postinstillation period
1 day 1 week 1 month 3 months
PBS+1% Tween 80 0.79±0.11 0.79±0.10 0.75±0.23 0.72±0.20
CI 1 mg/kg 0.80±0.17 0.81±0.14 0.88±0.15 0.82±0.19
CI 5 mg/kg 0.82±1.12 0.82±0.18 0.91±0.18 0.84±0.16
CNFs 1 mg/kg 1.04±0.25* 1.08±0.32* 1.29±0.32** 1.03±0.27
CNFs 5 mg/kg 1.29±0.28** 1.41±0.39*** 1.32±0.42** 1.12±0.35
MWCNTs 1 mg/kg 1.02±0.16* 1.06±0.25* 1.23±0.32* 1.02±0.29
MWCNTs 5 mg/kg 1.26±0.25** 1.36±0.40** 1.25±0.41** 1.08±0.16
CNRs 1 mg/kg 0.98±0.26 1.01±0.34* 1.12±0.34* 1.04±0.34
CNRs 5 mg/kg 1.23±0.31* 1.31±0.23** 1.23±0.36* 1.04±0.23
QZ 1 mg/kg 0.92±0.19 0.98±0.19 1.11±0.45* 1.07±0.35
QZ 5 mg/kg 1.22±0.23* 1.29±0.36** 1.21±0.39* 1.03±0.26
Data were expressed as mean±SD (n=6); Significance was indicated by *p<0.05, **p<0.01, ***p<0.001 versus control treated rats. BPS: Phosphate buffer saline, 
CI: Carbonyl iron, CNFs: Carbon nanofibers, MWCNTs: Multi wall carbon nanotubes, CNRs: Carbon nanorods, QZ: Quartz, SD: Standard deviation
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from the control group and each of the groups exposed to particulates, 
and the statistical significance was judged at the 0.05 probability level. 
Significance was indicated by: *p<0.05, **p<0.01, ***p<0.001 versus 
control (n=6).
RESULTS
Similar to the QZ, exposures of CNFs, MWCNTs, and CNRs in rats 
resulted in a dose-dependent increase in ALT levels at all postexposure 
periods (Table 1), but the significant (p<0.001) increase in ALT levels 
were observed with 5 mg/kg doses of all CNMs.
Intratracheal instillation of CNFs, MWCNTs, and CNRs in rats resulted 
in a dose-dependent increase in creatinine levels at all postexposure 
periods (Table 2), but the significant (p<0.001) increase in creatinine 
levels were observed with 5 mg/kg dose at 1 week of postinstillation 
period of CNFs.
The liver and kidney tissues exposed to various CNMs were isolated 
at 1 day, 1 week, 1 month, and 3 months postexposure periods and 
the histopathological changes were presented in Figs. 1 and 4. 
The rat livers after 1 week and 1 month postinstillation periods 
have shown congestion of central vein, shrinkage or ballooming of 
Fig. 1: Light micrograph of rat liver tissue at 1 week postinstillation exposure; control: PBS+1% Tween 80; 1WF1L: CNF (1 mg/kg); 1WF2L: 
CNF (5 mg/kg); 1WM1L: MWCNT (1 mg/kg); 1WM2L: MWCNT (5 mg/kg); 1WR1L: CNR (1 mg/kg); 1WR2L: CNR (5 mg/kg); 1WQ1L: Quartz 
(1 mg/kg); 1WQ2L: Quartz (5 mg/kg)
Fig. 2: Light micrograph of rat liver tissue at 1 month postinstillation exposure; control: PBS+1% Tween 80; 1MF1L: CNF (1 mg/kg); 
1MF2L: CNF (5 mg/kg); 1MM1L: MWCNT (1 mg/kg); 1MM2L: MWCNT (5 mg/kg); 1MR1L: CNR (1 mg/kg); 1MR2L: CNR (5 mg/kg) 
1MQ1L: Quartz (1mg/kg); 1MQ2L: Quartz (5 mg/kg)
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hepatocytes, necrosis, and degeneration with fat globules. There were 
no remarkable changes in liver tissue during 1 day and 3 months 
postexposure periods.
The histology of rat kidneys after 1 week and 1 month postexposure 
was displayed tubular dilation, increased inflammatory infiltrates, 
thinned outer cortex, focal areas showing necrosis and degeneration. 
There were no remarkable changes were found in the kidneys after 
1 day and 3 months postexposure periods.
DISCUSSION
This study investigated the ability of the different types of carbon 
nanoparticles to translocate into extrapulmonary organs such as 
Fig. 4: Light micrograph of rat kidney tissue at 1 month postinstillation exposure; control: PBS+1% Tween 80; 1MF1K: CNF (1 mg/kg); 
1MF2K: CNF (5 mg/kg); 1MM1K: MWCNT (1 mg/kg); 1MM2K: MWCNT (5 mg/kg); 1MR1K: CNR (1 mg/kg); 1MR2K: CNR (5 mg/kg); 
1MQ1K: Quartz (1 mg/kg); 1MQ2K: Quartz (5 mg/kg)
liver and kidney, and also evaluated the extrapulmonary toxicity in 
rats following intratracheal instillation of CNMs. Exposure of these 
CNMs at different doses does not produce any mortality in exposed 
rats. Exposure of QZ and these CNMs produced a dose-dependent 
periportal lymphocytic infiltration, congestion of sinusoids, ballooning, 
foamy degeneration of hepatocytes, fatty changes and finally focal 
inflammation and necrosis at 1 week and 1 month postinstillation 
periods. However, the significant tubular necrosis and interstitial 
nephritis take place with a dose of 5 mg/kg at 1 week of postinstillation 
of CNFs.
Exposures of these CNMs produced progressive liver and kidney 
damage which were confirmed by elevated levels of respective 
Fig. 3: Light micrograph of rat kidney tissue at 1 week postinstillation exposure; control: PBS+1% Tween 80; 1WF1K: CNF (1 mg/kg), 
1WF2K: CNF (5 mg/kg) WM1K: MWCNT (1 mg/kg); 1WM2K: MWCNT (5 mg/kg); 1WR1K: CNR (1 mg/kg); 1WR2K: CNR (5 mg/kg); 
1WQ1K: Quartz (1 mg/kg); 1WQ2K: Quartz (5 mg/kg)
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biomarkers of cell injury and inflammation. Analysis of serum for tissue 
damage biomarkers (serum ALT and creatinine) levels revealed that 
these enzyme levels in CNMs exposed rats (1 and 5 mg/kg b.w) were 
significantly higher than control at all the mentioned postexposure 
periods. The results of this study also showed the greater toxicity of 
CNFs than MWCNTs and CNRs.
Some of the reported the pulmonary toxicities induced by different 
CNMs such as single wall carbon nanotubes, MWCNTs and CNFs 
following intratracheal instillation in rats after 1 day, 1 week, 
1 month, and 3 months postexposure periods [19-21]. However, 
our results suggest the dose-dependent extra-pulmonary (liver and 
kidney) toxicities of intratracheally instilled CNFs, MWCNTs, and 
CNRs in rats, which was further confirmed by the histopathological 
examination of these organs of particle exposed rats. These 
extrapulmonary toxicities of CNMs might be due to the translocation 
into the liver and kidneys.
Once the particles have reached pulmonary interstitial sites, uptake 
into the blood circulation in addition to lymphatic pathways can 
occur, a pathway that again is dependent on particle size, favoring 
nanosized particles. Translocation of nanoparticles from the lung to the 
blood and extrapulmonary organs has been documented for various 
nanoparticles. For example, 60 minutes after intratracheal instillation 
of hamsters with nanocolloid albumin labeled with technetium-99m, 
detectable levels of the labeled nanoparticles were found in the blood, 
liver, heart, spleen, kidneys, and brain [13]. In ththis study also, MWCNT 
translocate mainly into the liver and produces liver toxicity than other 
extra-pulmonary sites.
Berry et al. was the first to describe translocation of nano sized particles 
across the alveolar epithelium using intratracheal instillations of 30 nm 
gold particles in rats [22]. Evidence in humans for the translocation of 
inhaled NSP into the blood circulation is ambiguous, with one study 
showing rapid appearance in the blood and significant accumulation 
of label in the liver of humans inhaling 99Tc-labelled 20 nm carbon 
particles [12], while another study using the same labeled particles 
reported no such accumulation [23].
Taken together all of the evidence from animal and human studies for 
alveolar translocation of various nanoparticles, it is likely that this 
pathway exists in humans as well; however, in addition to particle 
size, the extent of extrapulmonary translocation is highly dependent 
on particle surface chemistry, the amount of inhaled nanoparticles 
and potential degradation by lysosomal enzymes before transport 
to the lymphatic circulation. Translocation to the blood circulation 
could provide a mechanism for a direct particle effect on the 
cardiovascular system as an explanation for epidemiological findings 
of cardiovascular effects associated with inhaled ambient ultra fine 
particles [24-26]. All these above studies were supported our results 
for translocation and extrapulmonary toxicity induced by the test 
CNMs.
CONCLUSION
In summary, the intratracheal instillation of test CNMs increased 
the serum ALT and creatinine levels following 1 day, 1 week and 
1 month postexposure periods resulting in liver and kidney toxicity, 
respectively. This further confirmed by histopathological analysis of 
liver and kidneys. The order of extrapulmonary toxicity induced by the 
test CNMs was CNFs > MWCNTs > CNRs. Finally, the CNFs, MWCNTs, 
and CNRs able to translocate from the lungs into other extrapulmonary 
organs such as liver and kidney, and also cause dose-dependent toxicity 
to them.
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